Cardiovascular Atherosclerosis 2026: Prediction, Prevention and Management

Cardiovascular Atherosclerosis 2026: Prediction, Prevention and Management is organized by Scripps Health and will be held on Sep 19, 2026 at Schaetzel Center, La Jolla, California, United States of America.

Description:
Despite notable advances in management, atherosclerotic cardiovascular disease (ASCVD) and its major clinical manifestations continue to be a leading cause of morbidity and mortality worldwide. In the United States alone, ASCVD remains the leading cause of death across most racial and ethnic populations and carries an estimated annual cost exceeding $200 billion, driven by health care service utilization, medications, and productivity losses. These significant human and economic costs are often attributable to gaps in the implementation of effective prevention strategies and the underutilization of available medications and lifestyle interventions to control ASCVD risk factors.

The Scripps Cardiovascular Atherosclerosis conference is specifically designed to empower clinicians with the knowledge and tools necessary to enhance the prevention, diagnosis, treatment, and long-term management of ASCVD within their clinical practices. The conference also seeks to promote awareness of evidence-based lifestyle and dietary interventions, offering actionable insights to improve patient outcomes and reduce the overall burden of ASCVD. By addressing these challenges, this educational program will serve as a vital resource for health care providers committed to reducing the impact of ASCVD at both the individual and population levels.

Objectives:
Upon completion of this activity, participants should be able to:

1. Accurately assess cardiometabolic risk to guide ASCVD prevention strategies.
2. Analyze plaque characteristics and evaluate the clinical utility of new coronary imaging software technologies in the diagnosis and management of atherosclerosis.
3. Apply evidence-based approaches for screening, evaluating, and treating uncontrolled or resistant hypertension to improve patient outcomes.
4. Identify strategies to minimize the progression of chronic kidney disease (CKD) and mitigate its associated risks of atherosclerosis and adverse cardiovascular outcomes, with a focus on the role of RAAS and aldosterone modulation.
5. Evaluate the impact of genetically inherited cardiovascular risks and integrate polygenic risk scoring into prevention strategies for cardiovascular disease (CVD).
6. Review the latest advancements in hyperlipidemia management, including the role of CETP inhibitors, and their clinical implications.
7. Explore the role of artificial intelligence in cardiovascular medicine and its potential to enhance clinical decision-making and patient care.